Simsen Diagnostics

Executive Summary

Simsen Diagnostics is a Swedish biotechnology company founded in 2018 that specializes in ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) analysis. The company provides personalized diagnostic assays and end-to-end monitoring services to enable precise cancer detection, minimal residual disease (MRD) monitoring, and treatment response assessment for pharmaceutical companies, hospitals, and research institutions. Its core promise is to transform trace amounts of genetic material into actionable clinical truth. By leveraging a proprietary platform that achieves high sensitivity and specificity, Simsen aims to address critical unmet needs in oncology, particularly in the early detection of recurrence and real-time treatment monitoring. The company operates in a rapidly growing liquid biopsy market driven by the shift toward personalized medicine and non-invasive diagnostics. Simsen's technology offers competitive advantages in sensitivity and tumor-informed customization compared to standard ctDNA assays. While still in a private stage without disclosed funding, the company is positioned to capture value through partnerships with pharma and clinical adoption. Key near-term catalysts include potential collaboration announcements, clinical validation publications, and a Series A fundraise. With a strong scientific foundation and a clear value proposition, Simsen Diagnostics is well-placed to become a key player in the MRD monitoring space.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a pharmaceutical company for MRD monitoring services60% success
• Q2 2026Publication of clinical validation study in a peer-reviewed journal demonstrating assay sensitivity and specificity70% success
• Q4 2026Completion of Series A financing round to scale operations and commercialize platform50% success